Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging
Age-related macular degeneration is the leading cause of irreversible visual dysfunction in individuals over 65 in Western Society. Patients with AMD are classified as having early stage disease (early AMD), in which visual function is affected, or late AMD (generally characterized as either "w...
Saved in:
| Published in: | Investigative ophthalmology & visual science Vol. 54; no. 14; p. ORSF68 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
13.12.2013
|
| Subjects: | |
| ISSN: | 1552-5783, 1552-5783 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Age-related macular degeneration is the leading cause of irreversible visual dysfunction in individuals over 65 in Western Society. Patients with AMD are classified as having early stage disease (early AMD), in which visual function is affected, or late AMD (generally characterized as either "wet" neovascular AMD, "dry" atrophic AMD or both), in which central vision is severely compromised or lost. Until recently, there have been no therapies available to treat the disorder(s). Now, the most common wet form of late-stage AMD, choroidal neovascularization, generally responds to treatment with anti-vascular endothelial growth factor therapies. Nevertheless, there are no current therapies to restore lost vision in eyes with advanced atrophic AMD. Oral supplementation with the Age-Related Eye Disease Study (AREDS) or AREDS2 formulation (antioxidant vitamins C and E, lutein, zeaxanthin, and zinc) has been shown to reduce the risk of progression to advanced AMD, although the impact was in neovascular rather than atrophic AMD. Recent findings, however, have demonstrated several features of early AMD that are likely to be druggable targets for treatment. Studies have established that much of the genetic risk for AMD is associated with complement genes. Consequently, several complement-based therapeutic treatment approaches are being pursued. Potential treatment strategies against AMD deposit formation and protein and/or lipid deposition will be discussed, including anti-amyloid therapies. In addition, the role of autophagy in AMD and prevention of oxidative stress through modulation of the antioxidant system will be explored. Finally, the success of these new therapies in clinical trials and beyond relies on early detection, disease typing, and predicting disease progression, areas that are currently being rapidly transformed by improving imaging modalities and functional assays. |
|---|---|
| AbstractList | Age-related macular degeneration is the leading cause of irreversible visual dysfunction in individuals over 65 in Western Society. Patients with AMD are classified as having early stage disease (early AMD), in which visual function is affected, or late AMD (generally characterized as either "wet" neovascular AMD, "dry" atrophic AMD or both), in which central vision is severely compromised or lost. Until recently, there have been no therapies available to treat the disorder(s). Now, the most common wet form of late-stage AMD, choroidal neovascularization, generally responds to treatment with anti-vascular endothelial growth factor therapies. Nevertheless, there are no current therapies to restore lost vision in eyes with advanced atrophic AMD. Oral supplementation with the Age-Related Eye Disease Study (AREDS) or AREDS2 formulation (antioxidant vitamins C and E, lutein, zeaxanthin, and zinc) has been shown to reduce the risk of progression to advanced AMD, although the impact was in neovascular rather than atrophic AMD. Recent findings, however, have demonstrated several features of early AMD that are likely to be druggable targets for treatment. Studies have established that much of the genetic risk for AMD is associated with complement genes. Consequently, several complement-based therapeutic treatment approaches are being pursued. Potential treatment strategies against AMD deposit formation and protein and/or lipid deposition will be discussed, including anti-amyloid therapies. In addition, the role of autophagy in AMD and prevention of oxidative stress through modulation of the antioxidant system will be explored. Finally, the success of these new therapies in clinical trials and beyond relies on early detection, disease typing, and predicting disease progression, areas that are currently being rapidly transformed by improving imaging modalities and functional assays. Age-related macular degeneration is the leading cause of irreversible visual dysfunction in individuals over 65 in Western Society. Patients with AMD are classified as having early stage disease (early AMD), in which visual function is affected, or late AMD (generally characterized as either "wet" neovascular AMD, "dry" atrophic AMD or both), in which central vision is severely compromised or lost. Until recently, there have been no therapies available to treat the disorder(s). Now, the most common wet form of late-stage AMD, choroidal neovascularization, generally responds to treatment with anti-vascular endothelial growth factor therapies. Nevertheless, there are no current therapies to restore lost vision in eyes with advanced atrophic AMD. Oral supplementation with the Age-Related Eye Disease Study (AREDS) or AREDS2 formulation (antioxidant vitamins C and E, lutein, zeaxanthin, and zinc) has been shown to reduce the risk of progression to advanced AMD, although the impact was in neovascular rather than atrophic AMD. Recent findings, however, have demonstrated several features of early AMD that are likely to be druggable targets for treatment. Studies have established that much of the genetic risk for AMD is associated with complement genes. Consequently, several complement-based therapeutic treatment approaches are being pursued. Potential treatment strategies against AMD deposit formation and protein and/or lipid deposition will be discussed, including anti-amyloid therapies. In addition, the role of autophagy in AMD and prevention of oxidative stress through modulation of the antioxidant system will be explored. Finally, the success of these new therapies in clinical trials and beyond relies on early detection, disease typing, and predicting disease progression, areas that are currently being rapidly transformed by improving imaging modalities and functional assays.Age-related macular degeneration is the leading cause of irreversible visual dysfunction in individuals over 65 in Western Society. Patients with AMD are classified as having early stage disease (early AMD), in which visual function is affected, or late AMD (generally characterized as either "wet" neovascular AMD, "dry" atrophic AMD or both), in which central vision is severely compromised or lost. Until recently, there have been no therapies available to treat the disorder(s). Now, the most common wet form of late-stage AMD, choroidal neovascularization, generally responds to treatment with anti-vascular endothelial growth factor therapies. Nevertheless, there are no current therapies to restore lost vision in eyes with advanced atrophic AMD. Oral supplementation with the Age-Related Eye Disease Study (AREDS) or AREDS2 formulation (antioxidant vitamins C and E, lutein, zeaxanthin, and zinc) has been shown to reduce the risk of progression to advanced AMD, although the impact was in neovascular rather than atrophic AMD. Recent findings, however, have demonstrated several features of early AMD that are likely to be druggable targets for treatment. Studies have established that much of the genetic risk for AMD is associated with complement genes. Consequently, several complement-based therapeutic treatment approaches are being pursued. Potential treatment strategies against AMD deposit formation and protein and/or lipid deposition will be discussed, including anti-amyloid therapies. In addition, the role of autophagy in AMD and prevention of oxidative stress through modulation of the antioxidant system will be explored. Finally, the success of these new therapies in clinical trials and beyond relies on early detection, disease typing, and predicting disease progression, areas that are currently being rapidly transformed by improving imaging modalities and functional assays. |
| Author | Toth, Cynthia A Klingeborn, Mikael Farsiu, Sina Bowes Rickman, Catherine |
| Author_xml | – sequence: 1 givenname: Catherine surname: Bowes Rickman fullname: Bowes Rickman, Catherine organization: Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina – sequence: 2 givenname: Sina surname: Farsiu fullname: Farsiu, Sina – sequence: 3 givenname: Cynthia A surname: Toth fullname: Toth, Cynthia A – sequence: 4 givenname: Mikael surname: Klingeborn fullname: Klingeborn, Mikael |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24335072$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LxDAYhIOsuB969Co9erBrkzRN1pusn7AgiJ7L2-RtN9Kma5Iu7L-34AqeZhgehmHmZOJ6h4Rc0mxJaSFvbb8PS8pTyqSQJ2RGhWCpkIpP_vkpmYfwlWWMUpadkSnLOReZZDPy_uAPCTSYemwhokk60EMLPjHYoEMP0fbuLulQb8HZ0IWbJG7HeIdDtDqJ4BuMYwjOJLaDxrrmnJzW0Aa8OOqCfD49fqxf0s3b8-v6fpNqrmRMK5NxRFXoFdO05pWUBa6YYivGa1UhGE5BZQbkSNPC5AUqJQwHBnVRC6zYglz_9u58_z1giGVng8a2BYf9EEqaSymKXFI5oldHdKg6NOXOj1v9ofz7gf0AbyZhtg |
| CitedBy_id | crossref_primary_10_1111_aos_13753 crossref_primary_10_1111_aos_14721 crossref_primary_10_5604_01_3001_0014_2495 crossref_primary_10_1016_j_tcb_2019_10_001 crossref_primary_10_1038_s41598_022_26012_5 crossref_primary_10_3390_vision1020014 crossref_primary_10_1002_path_5447 crossref_primary_10_1016_j_drudis_2019_01_023 crossref_primary_10_1016_j_molmed_2018_04_004 crossref_primary_10_3390_vision1020011 crossref_primary_10_1177_2474126419865990 crossref_primary_10_3390_ijms21155563 crossref_primary_10_3390_a12030051 crossref_primary_10_1002_lipd_12306 crossref_primary_10_3389_fimmu_2023_1097456 crossref_primary_10_1016_j_oftal_2016_10_006 crossref_primary_10_3390_biomedicines13040986 crossref_primary_10_3390_molecules27165089 crossref_primary_10_70313_2718_7446_v17_n04_368 crossref_primary_10_1097_MS9_0000000000002888 crossref_primary_10_1167_iovs_65_2_42 crossref_primary_10_1167_iovs_61_2_32 crossref_primary_10_1016_j_heliyon_2024_e39100 crossref_primary_10_3390_cells13010050 crossref_primary_10_1088_2057_1976_ade9c7 crossref_primary_10_1111_aos_15803 crossref_primary_10_1089_jop_2021_0067 crossref_primary_10_3389_fnagi_2014_00191 crossref_primary_10_1146_annurev_vision_082114_035609 crossref_primary_10_1007_s10495_015_1091_7 crossref_primary_10_1111_jpi_12643 crossref_primary_10_1038_s41419_022_04691_2 crossref_primary_10_1016_j_biopha_2021_112501 crossref_primary_10_1038_srep41533 crossref_primary_10_1186_s12967_016_1101_8 crossref_primary_10_1038_s41684_024_01408_0 crossref_primary_10_1371_journal_pone_0125631 crossref_primary_10_7759_cureus_71479 crossref_primary_10_1167_iovs_64_15_45 crossref_primary_10_1167_iovs_62_12_8 crossref_primary_10_1016_j_fmre_2023_02_028 crossref_primary_10_1002_adhm_202501730 crossref_primary_10_3390_ijms22031296 crossref_primary_10_1016_j_exer_2019_107746 crossref_primary_10_1155_2015_875961 crossref_primary_10_1007_s00441_015_2185_9 crossref_primary_10_3928_23258160_20160126_06 crossref_primary_10_1093_hmg_ddx181 crossref_primary_10_1016_j_ajpath_2021_06_008 crossref_primary_10_1371_journal_pone_0178305 crossref_primary_10_3390_ijms20225800 crossref_primary_10_1016_j_oftale_2017_01_001 crossref_primary_10_1038_s41598_025_93993_4 crossref_primary_10_4103_1673_5374_155427 crossref_primary_10_1186_s12906_023_03884_2 crossref_primary_10_1139_bcb_2015_0120 crossref_primary_10_1111_php_13781 crossref_primary_10_1016_j_exer_2018_07_017 crossref_primary_10_3390_jpm11121329 crossref_primary_10_1083_jcb_201410112 crossref_primary_10_3389_fmolb_2022_860375 crossref_primary_10_1016_j_exer_2017_05_007 crossref_primary_10_1091_mbc_e14_05_1028 crossref_primary_10_7189_jogh_07_020703 crossref_primary_10_3390_ijms24076363 crossref_primary_10_3390_nu14204273 crossref_primary_10_1080_14728222_2020_1737015 crossref_primary_10_1007_s12272_016_0839_0 crossref_primary_10_1016_j_freeradbiomed_2018_11_035 crossref_primary_10_1080_15548627_2017_1380124 crossref_primary_10_1016_j_exer_2015_07_007 crossref_primary_10_3390_jcm9092869 crossref_primary_10_7554_eLife_81208 crossref_primary_10_1002_jmv_29478 crossref_primary_10_1016_j_jff_2016_08_046 crossref_primary_10_1016_j_neuroscience_2025_03_039 crossref_primary_10_3389_fnins_2022_1029473 crossref_primary_10_4103_npmj_npmj_9_24 crossref_primary_10_1074_jbc_RA119_012305 crossref_primary_10_1007_s00417_022_05858_5 crossref_primary_10_1007_s00417_014_2698_z crossref_primary_10_1007_s00417_024_06633_4 crossref_primary_10_3390_antiox11071304 crossref_primary_10_3892_etm_2017_4719 crossref_primary_10_1155_2020_8866961 crossref_primary_10_1016_j_imbio_2016_01_004 crossref_primary_10_1155_2015_569392 crossref_primary_10_1038_s41598_017_05102_9 crossref_primary_10_1016_j_preteyeres_2017_06_005 crossref_primary_10_1186_s40246_020_00257_5 crossref_primary_10_1038_s41467_018_04117_8 crossref_primary_10_1016_j_exer_2021_108800 crossref_primary_10_1080_14712598_2021_1945030 crossref_primary_10_1016_j_exer_2024_110050 crossref_primary_10_1016_j_jpba_2015_10_010 crossref_primary_10_1109_TMI_2016_2611503 crossref_primary_10_1038_cddis_2016_133 crossref_primary_10_3390_molecules24224197 crossref_primary_10_1016_j_exer_2021_108918 crossref_primary_10_1080_02713683_2022_2053725 crossref_primary_10_3390_molecules25030663 crossref_primary_10_1016_j_ajpath_2014_08_026 crossref_primary_10_1186_s40360_020_00471_w crossref_primary_10_1016_j_jconrel_2018_05_014 crossref_primary_10_3389_fphar_2020_566699 crossref_primary_10_5966_sctm_2014_0205 crossref_primary_10_1016_j_exer_2024_110177 crossref_primary_10_1080_15384101_2015_1080399 crossref_primary_10_3390_cells11132075 crossref_primary_10_3390_metabo13020187 crossref_primary_10_5966_sctm_2014_0079 crossref_primary_10_1089_jop_2018_0077 crossref_primary_10_1038_s41419_022_05433_0 crossref_primary_10_1093_hmg_ddac020 crossref_primary_10_1167_iovs_66_12_41 crossref_primary_10_1016_j_preteyeres_2018_02_002 crossref_primary_10_1016_j_yexcr_2020_111957 crossref_primary_10_3389_fncel_2024_1442079 crossref_primary_10_1155_2017_4128061 crossref_primary_10_1016_j_exer_2018_12_011 crossref_primary_10_3390_nu15030671 crossref_primary_10_1097_IAE_0000000000001535 crossref_primary_10_1016_j_preteyeres_2017_04_004 crossref_primary_10_1155_2022_3941952 crossref_primary_10_1073_pnas_1805039115 crossref_primary_10_1517_14728222_2014_988707 crossref_primary_10_3390_nu13124411 crossref_primary_10_1155_2019_5637075 crossref_primary_10_3389_fmed_2022_854629 crossref_primary_10_1016_j_survophthal_2024_11_009 crossref_primary_10_1016_j_bbrc_2016_10_140 crossref_primary_10_3390_ijms24054322 crossref_primary_10_1007_s12272_023_01482_x crossref_primary_10_1159_000503295 crossref_primary_10_1002_jex2_116 crossref_primary_10_1016_j_exer_2021_108586 crossref_primary_10_3390_ijms241512090 crossref_primary_10_3390_ijms19082317 crossref_primary_10_3390_antiox10081253 crossref_primary_10_1038_s41419_019_2216_7 crossref_primary_10_1038_s41419_020_2540_y crossref_primary_10_1194_jlr_M084442 crossref_primary_10_3389_fnins_2023_1232532 crossref_primary_10_7555_JBR_37_20230320 crossref_primary_10_1073_pnas_1523061113 crossref_primary_10_3390_bioengineering9080366 crossref_primary_10_3390_molecules26020313 crossref_primary_10_1016_j_ajo_2014_12_010 crossref_primary_10_1038_s41598_023_46029_8 crossref_primary_10_4137_OED_S32200 crossref_primary_10_1167_iovs_63_8_17 crossref_primary_10_1038_s41598_023_35099_3 crossref_primary_10_1080_09286586_2017_1337911 crossref_primary_10_1016_j_jff_2017_10_009 crossref_primary_10_1016_j_ajo_2016_11_014 crossref_primary_10_3390_ijms20040926 crossref_primary_10_1080_02713683_2025_2469235 crossref_primary_10_1186_s13036_018_0124_5 crossref_primary_10_1016_j_exer_2024_110111 crossref_primary_10_1016_j_mam_2017_10_002 crossref_primary_10_1167_iovs_66_4_58 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1167/iovs.13-12757 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1552-5783 |
| ExternalDocumentID | 24335072 |
| Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NEI NIH HHS grantid: R01 EY019038 – fundername: NEI NIH HHS grantid: P30 EY005722 – fundername: NEI NIH HHS grantid: EY019038 |
| GroupedDBID | --- 18M 2WC 34G 39C 5GY 5RE ACGFO ACNCT ADBBV AENEX AFOSN ALMA_UNASSIGNED_HOLDINGS BAWUL CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P GROUPED_DOAJ GX1 N9A NPM OK1 P2P RPM SJN TR2 TRV W8F WH7 WOQ WOW 7X8 |
| ID | FETCH-LOGICAL-c387t-bd03ee86c92c1f3b776e9282923f8bead31a80da738716d46e885d3a2af6f5eb2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 217 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000328884600013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1552-5783 |
| IngestDate | Fri Sep 05 13:42:53 EDT 2025 Thu Apr 03 07:00:16 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 14 |
| Keywords | autophagy functional imaging therapeutic targets complement drusen |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c387t-bd03ee86c92c1f3b776e9282923f8bead31a80da738716d46e885d3a2af6f5eb2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://iovs.arvojournals.org/arvo/content_public/journal/iovs/932982/i1552-5783-54-14-orsf68.pdf |
| PMID | 24335072 |
| PQID | 1477564717 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1477564717 pubmed_primary_24335072 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-12-13 |
| PublicationDateYYYYMMDD | 2013-12-13 |
| PublicationDate_xml | – month: 12 year: 2013 text: 2013-12-13 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Investigative ophthalmology & visual science |
| PublicationTitleAlternate | Invest Ophthalmol Vis Sci |
| PublicationYear | 2013 |
| References | 23562078 - Cell Metab. 2013 Apr 2;17(4):549-61 16949576 - Exp Eye Res. 2006 Nov;83(5):1295-302 16723483 - Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2655-61 17888483 - Vision Res. 2008 Feb;48(3):339-45 11425675 - Ophthalmology. 2001 Jul;108(7):1196-202 10213241 - Retina. 1999;19(2):141-7 21035861 - Ophthalmology. 2011 Apr;118(4):679-86 19797228 - Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2149-57 17921253 - Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16651-6 20940837 - Opt Express. 2010 Aug 30;18(18):19413-28 22503691 - Mol Aspects Med. 2012 Aug;33(4):418-35 7534250 - Graefes Arch Clin Exp Ophthalmol. 1994 Dec;232(12):707-16 11594957 - Arch Ophthalmol. 2001 Oct;119(10):1533-4 7678730 - Arch Ophthalmol. 1993 Jan;111(1):104-9 17909628 - J Clin Invest. 2007 Oct;117(10):2920-8 18486216 - Ophthalmology. 2008 Sep;115(9):1480-8, 1488.e1-2 18549781 - Neuron. 2008 Jun 12;58(5):681-93 3421236 - Am J Epidemiol. 1988 Oct;128(4):700-10 22510306 - Mol Aspects Med. 2012 Aug;33(4):399-417 11846519 - Exp Eye Res. 2001 Dec;73(6):887-96 23033386 - Invest Ophthalmol Vis Sci. 2012;53(11):7310-4 16286620 - Arch Ophthalmol. 2005 Nov;123(11):1570-4 19225789 - Acta Neuropathol. 2009 Jul;118(1):115-30 1957169 - Science. 1991 Nov 22;254(5035):1178-81 21969589 - Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18277-82 9022098 - Ophthalmology. 1997 Jan;104(1):7-21 23357621 - Ophthalmology. 2013 Apr;120(4):821-8 23352193 - Ophthalmology. 2013 May;120(5):1038-45 12189211 - Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11830-5 15761120 - Science. 2005 Apr 15;308(5720):419-21 23704555 - Science. 2013 May 24;340(6135):924-f 22254171 - Biomed Opt Express. 2012 Jan 1;3(1):86-103 23704554 - Science. 2013 May 24;340(6135):924-e 11359930 - Mol Biol Cell. 2001 May;12(5):1393-407 19380253 - Trends Mol Med. 2009 May;15(5):217-24 22447858 - Invest Ophthalmol Vis Sci. 2012;53(6):2921-7 23332590 - Ophthalmology. 2013 Apr;120(4):844-51 15249366 - Arch Ophthalmol. 2004 Jul;122(7):1013-8 17867795 - J Biomed Opt. 2007 Jul-Aug;12(4):041206 4963693 - Arch Ophthalmol. 1967 Nov;78(5):641-9 11384575 - Am J Ophthalmol. 2001 Jun;131(6):767-81 10415410 - Brain Res. 1999 Jul 31;836(1-2):110-9 17652758 - Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3827-36 17965659 - Nat Neurosci. 2007 Nov;10(11):1387-94 11904436 - Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3842-7 22968202 - IEEE Trans Biomed Eng. 2012 Dec;59(12):3450-9 11979237 - Mol Vis. 2002 Apr 21;8:119-26 16908818 - Arch Ophthalmol. 2006 Aug;124(8):1151-62 23873086 - Nat Biotechnol. 2013 Aug;31(8):741-7 20054780 - Folia Neuropathol. 2009;47(4):289-99 20224750 - J Vis Impair Blind. 2008 Oct 1;102(10):600-610 23761845 - Biomed Opt Express. 2013 May 07;4(6):803-21 21415062 - Br J Ophthalmol. 2011 Apr;95(4):441-2 1281403 - Arch Ophthalmol. 1992 Dec;110(12):1701-8 23381957 - EMBO Mol Med. 2013 Mar;5(3):397-412 16723717 - Am J Pathol. 2006 Jun;168(6):2036-53 2786408 - Arch Ophthalmol. 1989 Jun;107(6):847-52 20547953 - Arch Ophthalmol. 2010 Jun;128(6):750-8 22522934 - Nature. 2012 May 3;485(7396):99-103 18992244 - Exp Eye Res. 2009 Mar;88(3):610-2 23245386 - Am J Ophthalmol. 2013 Jan;155(1):1-35.e13 16424154 - J Immunol. 2006 Feb 1;176(3):1305-10 21609235 - Semin Ophthalmol. 2011 May;26(3):216-24 19390692 - PLoS One. 2009;4(4):e5304 11594942 - Arch Ophthalmol. 2001 Oct;119(10):1417-36 20811159 - J Clin Invest. 2010 Sep;120(9):3033-41 15761121 - Science. 2005 Apr 15;308(5720):421-4 23577296 - Biomed Opt Express. 2013 Apr 1;4(4):619-34 18433435 - Neuropathology. 2008 Aug;28(4):351-65 16565405 - Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1646-52 23590900 - Autophagy. 2013 Jul;9(7):973-84 21750765 - Biomed Opt Express. 2011 Jul 1;2(7):1864-76 17021323 - N Engl J Med. 2006 Oct 5;355(14):1474-85 23265840 - Trends Mol Med. 2013 Jan;19(1):51-60 22998595 - BMC Cancer. 2012;12:421 11274085 - Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1051-6 19129916 - PLoS One. 2009;4(1):e4160 17429481 - J Opt Soc Am A Opt Image Sci Vis. 2007 May;24(5):1358-63 22323736 - Science. 2012 Mar 23;335(6075):1503-6 19961953 - Prog Retin Eye Res. 2010 Mar;29(2):95-112 19703486 - Vision Res. 2010 Mar 31;50(7):652-64 22003115 - Invest Ophthalmol Vis Sci. 2011;52(13):9457-69 20393117 - Invest Ophthalmol Vis Sci. 2010 Oct;51(10):4875-83 14715704 - FASEB J. 2004 Mar;18(3):562-4 16286610 - Arch Ophthalmol. 2005 Nov;123(11):1484-98 22567602 - Biomed Opt Express. 2012 May 1;3(5):1127-40 11978769 - Hum Mol Genet. 2002 May 1;11(9):1107-17 17634448 - N Engl J Med. 2007 Aug 9;357(6):553-61 18544495 - Int Rev Cell Mol Biol. 2008;266:207-47 17460294 - Invest Ophthalmol Vis Sci. 2007 May;48(5):2297-303 21890786 - Br J Ophthalmol. 2011 Dec;95(12):1638-45 8737929 - Brain Pathol. 1996 Apr;6(2):127-45 16518403 - Nat Genet. 2006 Apr;38(4):458-62 12391305 - Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14682-7 23553287 - Graefes Arch Clin Exp Ophthalmol. 2013 Jul;251(7):1821-7 16778876 - Nature. 2006 Jun 15;441(7095):819-20 18326750 - Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1200-9 23993787 - Ophthalmology. 2014 Jan;121(1):162-72 17981333 - Ophthalmology. 2008 Jun;115(6):1026-31 10634630 - Invest Ophthalmol Vis Sci. 2000 Jan;41(1):267-73 19085384 - Curr Eye Res. 2008 Nov;33(11):1011-3 21317216 - Br J Ophthalmol. 2011 Apr;95(4):569-73 10783137 - FASEB J. 2000 May;14(7):835-46 5640854 - Arch Ophthalmol. 1968 Mar;79(3):315-20 23846467 - IEEE Trans Med Imaging. 2013 Nov;32(11):2034-49 22575354 - Mol Aspects Med. 2012 Aug;33(4):376-98 21388687 - Ophthalmology. 2011 Jul;118(7):1373-9 10064614 - FASEB J. 1999 Mar;13(3):477-84 12076098 - Exp Eye Res. 2002 Apr;74(4):547-9 21117594 - Ophthalmic Surg Lasers Imaging. 2010 Nov-Dec;41 Suppl:S104-8 23704556 - Science. 2013 May 24;340(6135):924-g 12634111 - Exp Eye Res. 2003 Apr;76(4):463-71 23652490 - Invest Ophthalmol Vis Sci. 2013 Jun;54(6):3985-98 19541290 - Am J Ophthalmol. 2009 Sep;148(3):439-44 22868580 - Ophthalmic Res. 2012;48(4):186-91 22410568 - Invest Ophthalmol Vis Sci. 2012 Apr;53(4):2337-48 23704553 - Science. 2013 May 24;340(6135):924-d 15870199 - Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227-32 23704552 - Science. 2013 May 24;340(6135):924-c 22714893 - Invest Ophthalmol Vis Sci. 2012 Aug;53(9):5213-20 19270489 - Autophagy. 2009 May;5(4):563-4 22930575 - Lasers Surg Med. 2012 Oct;44(8):603-10 6698741 - Invest Ophthalmol Vis Sci. 1984 Feb;25(2):195-200 22039246 - Invest Ophthalmol Vis Sci. 2012 Jan;53(1):53-61 18313664 - Eur J Pharmacol. 2008 Apr 28;584(2-3):229-36 7933422 - JAMA. 1994 Nov 9;272(18):1413-20 15761122 - Science. 2005 Apr 15;308(5720):385-9 11587915 - Prog Retin Eye Res. 2001 Nov;20(6):705-32 12359593 - Ophthalmology. 2002 Oct;109(10):1767-79 21221051 - Retina. 2011 Feb;31(2):364-70 17405851 - J Leukoc Biol. 2007 Jun;81(6):1345-51 19892876 - Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1304-10 12208254 - Am J Ophthalmol. 2002 Sep;134(3):411-31 21690377 - Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):E279-87 19965817 - Br J Ophthalmol. 2010 Jul;94(7):918-25 17325182 - Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1342-7 21609223 - Semin Ophthalmol. 2011 May;26(3):114-20 23271600 - Sensors (Basel). 2013;13(1):334-66 15862166 - Exp Eye Res. 2005 May;80(5):595-606 7516148 - Arch Ophthalmol. 1994 Jun;112(6):813-8 11033038 - Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34 10562652 - Mol Vis. 1999 Nov 3;5:28 12096983 - Arch Ophthalmol. 2002 Jul;120(7):997; author reply 997-9 15208270 - FASEB J. 2004 Aug;18(11):1297-9 10865992 - Exp Eye Res. 2000 Apr;70(4):441-9 20428236 - PLoS One. 2010;5(4):e10329 23162711 - Biomed Opt Express. 2012 Nov 1;3(11):2720-32 22450218 - Curr Opin Ophthalmol. 2012 May;23(3):182-8 17568180 - Autophagy. 2007 Sep-Oct;3(5):413-6 15944936 - Histol Histopathol. 2005 Jul;20(3):857-63 21979047 - Nature. 2011 Oct 6;478(7367):76-81 9676703 - Am J Epidemiol. 1998 Jul 15;148(2):204-14 22482455 - Prog Mol Biol Transl Sci. 2012;107:327-53 17251485 - Invest Ophthalmol Vis Sci. 2007 Feb;48(2):833-8 22968145 - Ophthalmology. 2013 Jan;120(1):140-50 10562651 - Mol Vis. 1999 Nov 3;5:27 18235027 - Invest Ophthalmol Vis Sci. 2008 Feb;49(2):772-80 21057346 - Optom Vis Sci. 2010 Dec;87(12):930-41 17664009 - Ophthalmology. 2008 Feb;115(2):334-41 23074204 - Invest Ophthalmol Vis Sci. 2012 Nov;53(12):7833-46 23702979 - Nat Rev Immunol. 2013 Jun;13(6):438-51 17429482 - J Opt Soc Am A Opt Image Sci Vis. 2007 May;24(5):1364-72 21740956 - Prog Neurobiol. 2011 Sep 15;95(1):14-25 23232206 - Exp Eye Res. 2013 Feb;107:80-7 15234127 - Ophthalmology. 2004 Jul;111(7):1280-7 8460013 - Ophthalmology. 1993 Mar;100(3):406-14 19584817 - Mol Ther. 2009 Sep;17(9):1594-604 7862408 - Ophthalmology. 1995 Feb;102(2):205-10 19167082 - Ophthalmology. 2009 Mar;116(3):488-496.e2 12091909 - Nat Genet. 2002 Aug;31(4):424-8 22039251 - Invest Ophthalmol Vis Sci. 2011 Nov;52(12):9218-25 17532250 - Prog Retin Eye Res. 2007 Sep;26(5):516-54 21135502 - J Clin Invest. 2011 Jan;121(1):369-83 11853768 - Vision Res. 2002 Feb;42(4):517-25 22025673 - Mol Cell Biol. 2012 Jan;32(1):2-11 22567586 - Biomed Opt Express. 2012 May 1;3(5):927-42 11786071 - Arch Ophthalmol. 2002 Jan;120(1):100-1 |
| References_xml | – reference: 10865992 - Exp Eye Res. 2000 Apr;70(4):441-9 – reference: 22968145 - Ophthalmology. 2013 Jan;120(1):140-50 – reference: 19961953 - Prog Retin Eye Res. 2010 Mar;29(2):95-112 – reference: 3421236 - Am J Epidemiol. 1988 Oct;128(4):700-10 – reference: 21969589 - Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18277-82 – reference: 15944936 - Histol Histopathol. 2005 Jul;20(3):857-63 – reference: 19225789 - Acta Neuropathol. 2009 Jul;118(1):115-30 – reference: 19584817 - Mol Ther. 2009 Sep;17(9):1594-604 – reference: 20224750 - J Vis Impair Blind. 2008 Oct 1;102(10):600-610 – reference: 19270489 - Autophagy. 2009 May;5(4):563-4 – reference: 17325182 - Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1342-7 – reference: 11853768 - Vision Res. 2002 Feb;42(4):517-25 – reference: 17568180 - Autophagy. 2007 Sep-Oct;3(5):413-6 – reference: 1281403 - Arch Ophthalmol. 1992 Dec;110(12):1701-8 – reference: 15870199 - Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227-32 – reference: 17251485 - Invest Ophthalmol Vis Sci. 2007 Feb;48(2):833-8 – reference: 8737929 - Brain Pathol. 1996 Apr;6(2):127-45 – reference: 10634630 - Invest Ophthalmol Vis Sci. 2000 Jan;41(1):267-73 – reference: 15862166 - Exp Eye Res. 2005 May;80(5):595-606 – reference: 17532250 - Prog Retin Eye Res. 2007 Sep;26(5):516-54 – reference: 12076098 - Exp Eye Res. 2002 Apr;74(4):547-9 – reference: 23162711 - Biomed Opt Express. 2012 Nov 1;3(11):2720-32 – reference: 16286620 - Arch Ophthalmol. 2005 Nov;123(11):1570-4 – reference: 9022098 - Ophthalmology. 1997 Jan;104(1):7-21 – reference: 16565405 - Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1646-52 – reference: 16908818 - Arch Ophthalmol. 2006 Aug;124(8):1151-62 – reference: 12391305 - Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14682-7 – reference: 18544495 - Int Rev Cell Mol Biol. 2008;266:207-47 – reference: 18235027 - Invest Ophthalmol Vis Sci. 2008 Feb;49(2):772-80 – reference: 22503691 - Mol Aspects Med. 2012 Aug;33(4):418-35 – reference: 15761122 - Science. 2005 Apr 15;308(5720):385-9 – reference: 23704552 - Science. 2013 May 24;340(6135):924-c – reference: 22254171 - Biomed Opt Express. 2012 Jan 1;3(1):86-103 – reference: 21135502 - J Clin Invest. 2011 Jan;121(1):369-83 – reference: 17909628 - J Clin Invest. 2007 Oct;117(10):2920-8 – reference: 22039251 - Invest Ophthalmol Vis Sci. 2011 Nov;52(12):9218-25 – reference: 23873086 - Nat Biotechnol. 2013 Aug;31(8):741-7 – reference: 17664009 - Ophthalmology. 2008 Feb;115(2):334-41 – reference: 21117594 - Ophthalmic Surg Lasers Imaging. 2010 Nov-Dec;41 Suppl:S104-8 – reference: 21609235 - Semin Ophthalmol. 2011 May;26(3):216-24 – reference: 21740956 - Prog Neurobiol. 2011 Sep 15;95(1):14-25 – reference: 22930575 - Lasers Surg Med. 2012 Oct;44(8):603-10 – reference: 22567602 - Biomed Opt Express. 2012 May 1;3(5):1127-40 – reference: 23271600 - Sensors (Basel). 2013;13(1):334-66 – reference: 22567586 - Biomed Opt Express. 2012 May 1;3(5):927-42 – reference: 15761120 - Science. 2005 Apr 15;308(5720):419-21 – reference: 22450218 - Curr Opin Ophthalmol. 2012 May;23(3):182-8 – reference: 18313664 - Eur J Pharmacol. 2008 Apr 28;584(2-3):229-36 – reference: 17888483 - Vision Res. 2008 Feb;48(3):339-45 – reference: 15249366 - Arch Ophthalmol. 2004 Jul;122(7):1013-8 – reference: 15208270 - FASEB J. 2004 Aug;18(11):1297-9 – reference: 11978769 - Hum Mol Genet. 2002 May 1;11(9):1107-17 – reference: 21317216 - Br J Ophthalmol. 2011 Apr;95(4):569-73 – reference: 8460013 - Ophthalmology. 1993 Mar;100(3):406-14 – reference: 7933422 - JAMA. 1994 Nov 9;272(18):1413-20 – reference: 12091909 - Nat Genet. 2002 Aug;31(4):424-8 – reference: 10415410 - Brain Res. 1999 Jul 31;836(1-2):110-9 – reference: 23652490 - Invest Ophthalmol Vis Sci. 2013 Jun;54(6):3985-98 – reference: 17981333 - Ophthalmology. 2008 Jun;115(6):1026-31 – reference: 14715704 - FASEB J. 2004 Mar;18(3):562-4 – reference: 17921253 - Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16651-6 – reference: 23232206 - Exp Eye Res. 2013 Feb;107:80-7 – reference: 19129916 - PLoS One. 2009;4(1):e4160 – reference: 11786071 - Arch Ophthalmol. 2002 Jan;120(1):100-1 – reference: 17634448 - N Engl J Med. 2007 Aug 9;357(6):553-61 – reference: 11274085 - Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1051-6 – reference: 20940837 - Opt Express. 2010 Aug 30;18(18):19413-28 – reference: 11904436 - Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3842-7 – reference: 17965659 - Nat Neurosci. 2007 Nov;10(11):1387-94 – reference: 23562078 - Cell Metab. 2013 Apr 2;17(4):549-61 – reference: 16286610 - Arch Ophthalmol. 2005 Nov;123(11):1484-98 – reference: 17867795 - J Biomed Opt. 2007 Jul-Aug;12(4):041206 – reference: 22968202 - IEEE Trans Biomed Eng. 2012 Dec;59(12):3450-9 – reference: 20547953 - Arch Ophthalmol. 2010 Jun;128(6):750-8 – reference: 11425675 - Ophthalmology. 2001 Jul;108(7):1196-202 – reference: 22410568 - Invest Ophthalmol Vis Sci. 2012 Apr;53(4):2337-48 – reference: 21979047 - Nature. 2011 Oct 6;478(7367):76-81 – reference: 20054780 - Folia Neuropathol. 2009;47(4):289-99 – reference: 18992244 - Exp Eye Res. 2009 Mar;88(3):610-2 – reference: 16778876 - Nature. 2006 Jun 15;441(7095):819-20 – reference: 16723717 - Am J Pathol. 2006 Jun;168(6):2036-53 – reference: 16518403 - Nat Genet. 2006 Apr;38(4):458-62 – reference: 20811159 - J Clin Invest. 2010 Sep;120(9):3033-41 – reference: 2786408 - Arch Ophthalmol. 1989 Jun;107(6):847-52 – reference: 17429482 - J Opt Soc Am A Opt Image Sci Vis. 2007 May;24(5):1364-72 – reference: 22039246 - Invest Ophthalmol Vis Sci. 2012 Jan;53(1):53-61 – reference: 10783137 - FASEB J. 2000 May;14(7):835-46 – reference: 23704555 - Science. 2013 May 24;340(6135):924-f – reference: 6698741 - Invest Ophthalmol Vis Sci. 1984 Feb;25(2):195-200 – reference: 19541290 - Am J Ophthalmol. 2009 Sep;148(3):439-44 – reference: 12208254 - Am J Ophthalmol. 2002 Sep;134(3):411-31 – reference: 7862408 - Ophthalmology. 1995 Feb;102(2):205-10 – reference: 23352193 - Ophthalmology. 2013 May;120(5):1038-45 – reference: 12359593 - Ophthalmology. 2002 Oct;109(10):1767-79 – reference: 21750765 - Biomed Opt Express. 2011 Jul 1;2(7):1864-76 – reference: 16949576 - Exp Eye Res. 2006 Nov;83(5):1295-302 – reference: 22025673 - Mol Cell Biol. 2012 Jan;32(1):2-11 – reference: 11594942 - Arch Ophthalmol. 2001 Oct;119(10):1417-36 – reference: 19703486 - Vision Res. 2010 Mar 31;50(7):652-64 – reference: 23332590 - Ophthalmology. 2013 Apr;120(4):844-51 – reference: 11979237 - Mol Vis. 2002 Apr 21;8:119-26 – reference: 19380253 - Trends Mol Med. 2009 May;15(5):217-24 – reference: 19797228 - Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2149-57 – reference: 11587915 - Prog Retin Eye Res. 2001 Nov;20(6):705-32 – reference: 19965817 - Br J Ophthalmol. 2010 Jul;94(7):918-25 – reference: 16424154 - J Immunol. 2006 Feb 1;176(3):1305-10 – reference: 18486216 - Ophthalmology. 2008 Sep;115(9):1480-8, 1488.e1-2 – reference: 23245386 - Am J Ophthalmol. 2013 Jan;155(1):1-35.e13 – reference: 19390692 - PLoS One. 2009;4(4):e5304 – reference: 23761845 - Biomed Opt Express. 2013 May 07;4(6):803-21 – reference: 5640854 - Arch Ophthalmol. 1968 Mar;79(3):315-20 – reference: 10213241 - Retina. 1999;19(2):141-7 – reference: 22510306 - Mol Aspects Med. 2012 Aug;33(4):399-417 – reference: 22482455 - Prog Mol Biol Transl Sci. 2012;107:327-53 – reference: 11846519 - Exp Eye Res. 2001 Dec;73(6):887-96 – reference: 22998595 - BMC Cancer. 2012;12:421 – reference: 7516148 - Arch Ophthalmol. 1994 Jun;112(6):813-8 – reference: 22714893 - Invest Ophthalmol Vis Sci. 2012 Aug;53(9):5213-20 – reference: 9676703 - Am J Epidemiol. 1998 Jul 15;148(2):204-14 – reference: 12634111 - Exp Eye Res. 2003 Apr;76(4):463-71 – reference: 17021323 - N Engl J Med. 2006 Oct 5;355(14):1474-85 – reference: 19892876 - Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1304-10 – reference: 18433435 - Neuropathology. 2008 Aug;28(4):351-65 – reference: 7678730 - Arch Ophthalmol. 1993 Jan;111(1):104-9 – reference: 20393117 - Invest Ophthalmol Vis Sci. 2010 Oct;51(10):4875-83 – reference: 19167082 - Ophthalmology. 2009 Mar;116(3):488-496.e2 – reference: 21415062 - Br J Ophthalmol. 2011 Apr;95(4):441-2 – reference: 17429481 - J Opt Soc Am A Opt Image Sci Vis. 2007 May;24(5):1358-63 – reference: 21057346 - Optom Vis Sci. 2010 Dec;87(12):930-41 – reference: 7534250 - Graefes Arch Clin Exp Ophthalmol. 1994 Dec;232(12):707-16 – reference: 11594957 - Arch Ophthalmol. 2001 Oct;119(10):1533-4 – reference: 23993787 - Ophthalmology. 2014 Jan;121(1):162-72 – reference: 23704553 - Science. 2013 May 24;340(6135):924-d – reference: 21690377 - Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):E279-87 – reference: 23577296 - Biomed Opt Express. 2013 Apr 1;4(4):619-34 – reference: 21388687 - Ophthalmology. 2011 Jul;118(7):1373-9 – reference: 22003115 - Invest Ophthalmol Vis Sci. 2011;52(13):9457-69 – reference: 15761121 - Science. 2005 Apr 15;308(5720):421-4 – reference: 11359930 - Mol Biol Cell. 2001 May;12(5):1393-407 – reference: 11384575 - Am J Ophthalmol. 2001 Jun;131(6):767-81 – reference: 21221051 - Retina. 2011 Feb;31(2):364-70 – reference: 10562651 - Mol Vis. 1999 Nov 3;5:27 – reference: 17405851 - J Leukoc Biol. 2007 Jun;81(6):1345-51 – reference: 10064614 - FASEB J. 1999 Mar;13(3):477-84 – reference: 18326750 - Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1200-9 – reference: 23590900 - Autophagy. 2013 Jul;9(7):973-84 – reference: 22522934 - Nature. 2012 May 3;485(7396):99-103 – reference: 19085384 - Curr Eye Res. 2008 Nov;33(11):1011-3 – reference: 21609223 - Semin Ophthalmol. 2011 May;26(3):114-20 – reference: 22575354 - Mol Aspects Med. 2012 Aug;33(4):376-98 – reference: 23265840 - Trends Mol Med. 2013 Jan;19(1):51-60 – reference: 22447858 - Invest Ophthalmol Vis Sci. 2012;53(6):2921-7 – reference: 23074204 - Invest Ophthalmol Vis Sci. 2012 Nov;53(12):7833-46 – reference: 18549781 - Neuron. 2008 Jun 12;58(5):681-93 – reference: 23704556 - Science. 2013 May 24;340(6135):924-g – reference: 15234127 - Ophthalmology. 2004 Jul;111(7):1280-7 – reference: 12189211 - Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11830-5 – reference: 23381957 - EMBO Mol Med. 2013 Mar;5(3):397-412 – reference: 11033038 - Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34 – reference: 23704554 - Science. 2013 May 24;340(6135):924-e – reference: 4963693 - Arch Ophthalmol. 1967 Nov;78(5):641-9 – reference: 23357621 - Ophthalmology. 2013 Apr;120(4):821-8 – reference: 22868580 - Ophthalmic Res. 2012;48(4):186-91 – reference: 23846467 - IEEE Trans Med Imaging. 2013 Nov;32(11):2034-49 – reference: 17460294 - Invest Ophthalmol Vis Sci. 2007 May;48(5):2297-303 – reference: 10562652 - Mol Vis. 1999 Nov 3;5:28 – reference: 20428236 - PLoS One. 2010;5(4):e10329 – reference: 22323736 - Science. 2012 Mar 23;335(6075):1503-6 – reference: 23033386 - Invest Ophthalmol Vis Sci. 2012;53(11):7310-4 – reference: 12096983 - Arch Ophthalmol. 2002 Jul;120(7):997; author reply 997-9 – reference: 1957169 - Science. 1991 Nov 22;254(5035):1178-81 – reference: 16723483 - Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2655-61 – reference: 23553287 - Graefes Arch Clin Exp Ophthalmol. 2013 Jul;251(7):1821-7 – reference: 17652758 - Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3827-36 – reference: 21035861 - Ophthalmology. 2011 Apr;118(4):679-86 – reference: 21890786 - Br J Ophthalmol. 2011 Dec;95(12):1638-45 – reference: 23702979 - Nat Rev Immunol. 2013 Jun;13(6):438-51 |
| SSID | ssj0021120 |
| Score | 2.5524507 |
| SecondaryResourceType | review_article |
| Snippet | Age-related macular degeneration is the leading cause of irreversible visual dysfunction in individuals over 65 in Western Society. Patients with AMD are... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | ORSF68 |
| SubjectTerms | Angiogenesis Inhibitors - therapeutic use Antioxidants - therapeutic use Diagnostic Techniques, Ophthalmological Disease Management Disease Progression Dry Eye Syndromes - complications Dry Eye Syndromes - diagnosis Dry Eye Syndromes - therapy Humans Macular Degeneration - diagnosis Macular Degeneration - etiology Macular Degeneration - therapy Oxidative Stress |
| Title | Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24335072 https://www.proquest.com/docview/1477564717 |
| Volume | 54 |
| WOSCitedRecordID | wos000328884600013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qinjx_VhfRPBo3LZpk9SLiLp42WURhb2VpEmlh7brdl3w3ztJu-pFELzkUFIIk8nkm8zMNwhdhJ7mTGpJgkh6JBQ-JQruMZJmIgWA4Zs0UK7ZBB8OxXgcj9oHt7pNq1zYRGeodZXaN_KeH3IeMTCl_GbyRmzXKBtdbVtoLKMOBShjU7r4-CuKAL6No2W0LGMENJMuODYZ7-XVvL6ChVl-c_47unS3TH_zv-vbQhstvsS3jUJsoyVT7qC1QRtB30VP99MPDDaEuCIWo3EhXSYq1ubVMVDbjbrGhbEVwXld1Jf4R4kWbhLH4aMsNc4L1-JoD730H57vHknbV4GkVPAZUdqjxgiWxkHqZ1RxzkxsI6oBzYQC1aK-FJ6WnFpvSofMCBFpKgOZsSwCV3wfrZRVaQ4R1iFXnswiLSQIQCuAmx5TRsMkn9OYddH5QloJ6K0NRsjSVO918i2vLjpoRJ5MGoKNJAgpBZwaHP3h72O0HnhuI4lPT1Ang1NrTtFqOp_l9fTMKQSMw9HgEw9twQA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dry+age-related+macular+degeneration%3A+mechanisms%2C+therapeutic+targets%2C+and+imaging&rft.jtitle=Investigative+ophthalmology+%26+visual+science&rft.au=Bowes+Rickman%2C+Catherine&rft.au=Farsiu%2C+Sina&rft.au=Toth%2C+Cynthia+A&rft.au=Klingeborn%2C+Mikael&rft.date=2013-12-13&rft.issn=1552-5783&rft.eissn=1552-5783&rft.volume=54&rft.issue=14&rft.spage=ORSF68&rft_id=info:doi/10.1167%2Fiovs.13-12757&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-5783&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-5783&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-5783&client=summon |